Ariel Miller
机构: Prof. of Medicine (Neurology), Carmel Medical Center & Technion, Haifa, Israel
每年引用次数
引用次数
引用: 13,177
H-指数: 58
I10-指数 : 139
出版物: 300
Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression.
Ahmad Al-Sabbagh , H. L. Weiner , Mercy Prabhu Das , L. M. B. Santos
Journal of Immunology 151 ( 12) 7307 -7315
147
1993
Nonencephalitogenic CD4-CD8- V alpha 2V beta 8.2+ anti-myelin basic protein rat T lymphocytes inhibit disease induction.
Xiangming Zhang , S. Miron , R. Hershkoviz , A. Miller
Journal of Immunology 147 ( 4) 1208 -1213
27
1991
FATIGUE IN MS. AUTHOR'S REPLY
A. H. Cross , A. Miller , L. B. Krupp , H. Schutta
Neurology 47 ( 5)
1996
Pilot trial of Cop 1 in chronic progressive multiple sclerosis: Preliminary report
Stanley H. Appel , M. Sela , A. Miller , L. Rolak
The International Multiple Sclerosis Conference: an update on multiple sclerosis 225 -232
15
1989
A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting
D. Karussis , L. D. Biermann , S. Bohlega , A. Boiko
European Journal of Neurology 13 ( 1) 61 -71
46
2006
Chronotherapy using corticosteroids for multiple sclerosis relapses
L. Glass-Marmor , T. Paperna , Y. Ben-Yosef , A. Miller
Journal of Neurology, Neurosurgery, and Psychiatry 78 ( 8) 886 -888
27
2007
Laquinimod-Mediated Modulation of B Cells from Multiple Sclerosis Patients: Affecting Direct and Indirect Immune-Regulatory Functions (P02.116)
A. Miller , S. Nussbaum , E. Staun-Ram , A. Snir
Neurology 78
2012
Pharmacogenetic Development of Personalized Medicine: Multiple Sclerosis Treatment as a Model.
I. Kirstein-Grossman , J.S. Beckmann , D. Lancet , A. Miller
Drug News & Perspectives 15 ( 9) 558 -567
10
2002
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering.
A. Miller , O. Lider , A. B. Roberts , M. B. Sporn
Proceedings of the National Academy of Sciences of the United States of America 89 ( 1) 421 -425
673
1992
Matrix metalloproteinases (MMPs) and IL-8 CSF-levels are correlated with brain edema following cerebral infarction
C. Braker , S. Shapiro , N. Lahat , E. Sobel
Journal of Neuroimmunology 90 ( 1) 30
1
1998
Virtual reality cues for improvement of gait in patients with multiple sclerosis
Y. Baram , A. Miller
Neurology 66 ( 2) 178 -181
104
2006
Reply from the Authors Fatigue in MS
L.B. Krupp , P.K. Coyle , R. Grimson , A. Miller
Neurology 47 ( 5) 1351 -1351
2
1996
Intravenous immunoglobulin treatment in multiple sclerosis
G. Francis , A. Achiron , Y. Barak , N. Gadoth
Neurology 52 ( 1) 214 -214
2
1999
A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis
M. B. Bornstein , A. Miller , S. Slagle , M. Weitzman
Neurology 41 ( 4) 533 -533
178
1991
Treatment of autoimmune diseases by oral tolerance to autoantigens.
Sobel R , Brod Sa , al-Sabbagh A , Weiner Hl
Advances in Experimental Medicine and Biology 1217
5
1995
[Hospital-at-home as a solution for the treatment requirements of acute exacerbation in multiple sclerosis].
Almany A , Steinmetz D , Miller A , Berkovitz E
Harefuah 140 ( 7) 603
2
2001
The 15th Rappaport Symposium. Immune-mediated brain injury and repair: mechanisms and therapies. 15-16 June 2000, Haifa, Israel.
Miller A , Compston A , Martin R
Israel Medical Association Journal 3 ( 3) 233
2001
[The trimolecular complex as a target for specific immunotherapy in experimental autoimmune encephalomyelitis--applications for multiple sclerosis and other human autoimmune disease].
Abramsky O , Weiner Hl , Miller A
Harefuah 123 110
1992
Clinical experience with COP-1 in multiple sclerosis.
Keilson M , Slagle S , Crystal H , Bornstein Mb
Neurology 38 66
24
1988
Clinical trial design in multiple sclerosis therapy.
Slagle S , Bornstein Mb , Weiss W , Miller A
Neurology 38 80
13
1988